Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 EPS of $0.26, $0.08 better than the analyst estimate of $0.18. Revenue for the quarter came in at $57.2 million versus the consensus estimate of $53.62 million.

GUIDANCE:

Catalyst Pharmaceuticals sees FY2022 revenue of $205-210 million, versus the consensus of $205 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.